Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
Shinji Ohno(National Hospital Organization Kyushu Cancer Center), Masakazu Toi(Kyoto University)
Cited by 55
Related Papers
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
|British Journal of Cancer|2009|94
Prognostic significance of tumor/stromal caveolin‐1 expression in breast cancer patients
|Cancer Science|2011|62
Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast
|Frontiers in Oncology|2017|29